Bacci G, Mercuri M, Briccoli A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C, Manfrini M
Sezione di Chemioterapia, Istituto Ortopedico Rizzoli, Bologna, Italy.
Cancer. 1997 Jan 15;79(2):245-54.
In the past 20 years, it has been demonstrated that the combination of surgery and chemotherapy improves the prognosis for patients with osteosarcoma of the extremity without detectable metastases at presentation. By contrast, the efficacy of chemotherapy coupled with aggressive surgery has not yet been well established for patients with metastatic disease at diagnosis. The current study evaluates the efficacy of chemotherapy associated with simultaneous surgery of primary and metastatic lesions in patients presenting with osteosarcoma of the extremity with lung metastases.
Patients with lung metastases originating from an osteosarcoma of the extremity received chemotherapy (high dose methotrexate, cisplatin, doxorubicin, and ifosfamide) followed by simultaneous resection of primary and metastatic lesions and additional chemotherapy.
Between January 1993 and June 1995, 23 patients entered the study. After primary chemotherapy, lung metastases disappeared in three patients, whereas in four patients they remained surgically unresectable. All seven patients received surgical treatment of the primary tumor only. In the remaining 16 patients, a simultaneous resection of the primary and metastatic tumors was performed after chemotherapy. The resection of metastatic lesions resulted in a complete remission in 15 patients and an incomplete remission in 1 patient. All five patients who never achieved tumor free status died within a few months. Of the 18 patients who achieved radiologic remission at a 30-month follow-up (range, 14-50 months), 10 (55.5%) remained continuously free of disease, 7 relapsed with new metastases, and 1 died of toxicity. In 13 of the 18 patients who underwent a complete simultaneous resection of the primary and the metastatic lesions, or whose pulmonary metastases disappeared after chemotherapy, a strong correlation was found between degree of necrosis of the primary tumor and of the metastatic tumor.
In patients presenting with osteosarcoma of the extremity with lung metastases, the combination of aggressive chemotherapy with simultaneous resection of the primary and metastatic lesions improves traditionally negative outcomes. The strong correlation found between the histologic response of the primary and metastatic tumors supports the strategy, largely used currently in the neoadjuvant treatment of osteosarcoma, of tailoring postoperative chemotherapy on the basis of the histologic response of the primary tumor to preoperative chemotherapy.
在过去20年中,已证实手术与化疗相结合可改善初诊时无可检测转移灶的肢体骨肉瘤患者的预后。相比之下,对于诊断时有转移性疾病的患者,化疗联合积极手术的疗效尚未得到充分证实。本研究评估了化疗联合同期手术切除原发灶和转移灶对伴有肺转移的肢体骨肉瘤患者的疗效。
来自肢体骨肉瘤的肺转移患者接受化疗(大剂量甲氨蝶呤、顺铂、阿霉素和异环磷酰胺),随后同期切除原发灶和转移灶并进行额外化疗。
1993年1月至1995年6月,23例患者进入研究。初始化疗后,3例患者的肺转移灶消失,而4例患者的肺转移灶仍无法手术切除。所有7例患者仅接受了原发肿瘤的手术治疗。其余16例患者在化疗后同期切除了原发肿瘤和转移肿瘤。转移灶切除后,15例患者完全缓解,1例患者部分缓解。所有5例未达到无瘤状态的患者在几个月内死亡。在30个月随访(范围14 - 50个月)时达到影像学缓解的18例患者中,10例(55.5%)持续无病,7例出现新的转移灶复发,1例死于毒性反应。在18例同期完整切除原发灶和转移灶或化疗后肺转移灶消失的患者中,有13例患者的原发肿瘤和转移肿瘤坏死程度之间存在强相关性。
对于伴有肺转移的肢体骨肉瘤患者,积极化疗联合同期切除原发灶和转移灶可改善传统上较差的预后。原发肿瘤和转移肿瘤的组织学反应之间存在的强相关性支持了目前在骨肉瘤新辅助治疗中广泛使用的策略,即根据原发肿瘤对术前化疗的组织学反应来调整术后化疗。